SUMMARY
Development of hypoxic regions is an indicator of poor prognosis in many tumors. Here we demonstrate that HIF1α, the direct effector of hypoxia, partly through increases in SDF1α, induces recruitment of bone marrow-derived CD45+ myeloid cells containing Tie2+, VEGFR1+, CD11b+ and F4/80+ subpopulations, as well as endothelial and pericyte progenitor cells to promote neovascularization in glioblastoma. MMP-9 activity of bone marrow-derived CD45+ cells is essential and sufficient to initiate angiogenesis by increasing VEGF bioavailability. In the absence of HIF1α, SDF1α levels decrease, fewer BM-derived cells are recruited to the tumors, decreasing MMP-9 and mobilization of VEGF. VEGF also directly regulates tumor cell invasiveness. When VEGF activity is impaired tumor cells invade deep into the brain in the perivascular compartment.
SIGNIFICANCE
HIF1α activity in tumors is associated with poor clinical outcome as indicated by their highly angiogenic, invasive or metastatic nature. We found that HIF1α contributes to induction of SDF1α in tumor cells that in turn promotes tumor progression by recruiting vascular modulatory bone marrow-derived cells to stimulate angiogenesis. These results provide the molecular mechanism by which HIF1α contributes to aggressive tumor progression and provides a rational basis for future therapeutic modalities. The data also reveal a novel function for VEGF activity in directly affecting invasiveness of tumor cells. VEGF prevents tumor cell migration along blood vessels but promotes tumor cell infiltration into the brain parenchyma. Therefore, tumor cells use perivascular invasiveness as an evasive adaptation mechanism when angiogenesis is impaired.
INTRODUCTION
When tumors encounter low oxygen tension, they adapt by promoting expression of genes associated with anaerobic cell metabolism, cell survival, angiogenesis, metastasis and invasion. This transcriptional response pathway is mediated to a large extent by the dimeric transcription factor complexes of hypoxia-inducible factor HIF1 and HIF2 (Simon et al., 2002; Lofstedt et al., 2007) . At normoxia HIFα subunits are degraded, but they are stabilized and activated under hypoxic conditions and form complexes with the constitutively expressed transcription factor ARNT/HIF1β (Giaccia et al., 2004; Lofstedt et al., 2007; Maxwell, 2004) .
Genetic ablation of HIF1α in various tumors results in reduced tumor mass, increased apoptosis, and retarded metastasis due in part to reduced vascular density and inhibition of angiogenesis (Maxwell et al., 1997; Ryan et al., 1998; Liao et al., 2007; Blouw et al., 2003) . These data indicate that poor oxygenation, concomitant with HIF1α induction, is associated with a more aggressive tumor phenotype. Accordingly, HIF1α is a marker of poor prognosis for various tumors such as those of the breast, brain and lung (Mabjeesh and Amir, 2007; Semenza, 2002) .
Besides its direct effects on tumor cell behavior, HIF1 activity also influences the microenvironment to support tumor propagation and progression by enabling the tumor and host cells to produce a variety of proangiogenic factors like VEGF-A, VEGFR1, PDGF-B, FGF-2 and angiopoietins that stimulate new blood vessel formation within the hypoxic areas (Shweiki et al., 1992 ) (Calvani et al., 2006; Carmeliet et al., 1998; Faller, 1999; Holash et al., 1999; Okuyama et al., 2006; Simon et al., 2002) . New blood vessel formation in tumors and ischemic tissues is derived from the existing vasculature by activating and initiating proliferation and migration of endothelial cells (angiogenesis), as well as by recruitment of a heterogeneous population of bone marrow-derived cells (BMDCs), including endothelial progenitor cells (EPC) and pericyte progenitor cells (PPC) and CD45+ vascular modulatory cells (Aghi and Chiocca, 2005; De Palma et al., 2005; Grunewald et al., 2006; Heissig et al., 2002; Kopp et al., 2006; Lin et al., 2006; Lyden et al., 2001; Pollard, 2004; Rafii et al., 2003; Rajantie et al., 2004; Song et al., 2005) . While EPCs incorporate into the vasculature and differentiate into endothelial cells, PPCs envelope blood vessels and mature into pericytes and vascular smooth muscle cells.
The largest and most heterogeneous group of BMDCs are CD45+ cells of the monocytic lineage that function as vascular modulators, but are not physically part of the vasculature (Grunewald et al., 2006) . Such cells include tumorassociated macrophages (TAMs) (Pollard, 2004) and immature monocytic cells including Tie2+ monocytes (TEMs) (De Palma et al., 2005) , VEGFR1+
hemangiocytes Kaplan et al., 2005) and CD11b+ myeloid cells (Bunt et al., 2006; Yang et al., 2004) , all of which express the receptor CXCR4 to some extent. Little is known about the factors that enable the mobilization of BMDC from the bone marrow into the blood stream and their recruitment and retention into the tumor. The most prominent factors identified thus far include VEGF, PlGF and PDGF-B, which act as mobilization factors of EPCs and PPCs respectively (Gerhardt and Betsholtz, 2003; Hattori et al., 2001; Luttun et al., 2002; Rabbany et al., 2003) , and SDF1α, which can facilitate CXCR4+ BMDC retention within tumors (Grunewald et al., 2006; Hattori et al., 2003) . Furthermore, recent data have shown that ischemic tissues may recruit endothelial progenitors and other CXCR4+ BMDCs, in part through increases in HIF and its targets SDF1α and VEGF (Aghi et al., 2006; Ceradini et al., 2004; De Falco et al., 2004; Petit et al., 2007) . In this study, we test the hypothesis that hypoxic conditions in tumors as well as in normal tissues promote neovascularization in a HIF-dependent manner by mediating BMDC recruitment.
We were poised to assess this hypothesis in an orthotopic mouse model of glioblastoma (GBM, grade IV astrocytoma), because these aggressive brain tumors are very hypoxic and highly angiogenic (Zagzag et al., 2000) . We recently reported that loss of HIF1α activity in orthotopic GBM blocks vascular remodeling and angiogenesis (Blouw et al., 2003) . While tumor vessels in WT-GBM are hyperdilated, distorted and leaky, tumor vessels in HIFko GBM remain slim and regularly shaped being more reflective of the normal brain vasculature. HIF1αdeficient (HIFko) GBM, however, adapt to their inability to form new vessels by coopting and moving along blood vessels, a phenomenon defined as perivascular invasion, hence becoming more invasive (Blouw et al., 2003) . In the present study we inquired about the mechanisms by which HIF1α stimulates vascular remodeling and angiogenesis and blocks the perivascular invasive evasive adaptation mechanism.
RESULTS

HIF1 recruits bone marrow-derived cells to the tumor site
To test the hypothesis that GBMs promote BMDC-dependent neovascularization and do so in a HIF-dependent manner, we transplanted bone marrow cells from β-actin-EGFP mice into lethally irradiated Rag1-deficient (Ragko) mice. Four weeks later, mice were implanted intracranially with HIF1α-proficient (WT-GBM/HIFwt GBM) or HIF1α-deficient (HIFko GBM) GBM cells. When we analyzed the tumors, we found that GFP+ BMDC cells represented about 15-20% of all cells in WT-GBM tumors, whereas HIFko GBMs contained only about one-third this number ( Figure 1A ). Normal brain recruited virtually no GFP+ cells. GFP+ BMDC appeared randomly distributed within the tumor, but were predominantly located close to or adjacent to blood vessels in tumors ( Figure   1A ). Taken together, these results indicate that HIF1α activity promotes recruitment of a substantial number of BMDC in GBM.
We next assessed the BMDC types recruited by HIF1 by fluorescence activated cell sorting (FACS) and immunohistochemical analyses of the tumorderived GFP+ cell populations. WT-GBM elicited about three times more CD45 + monocytic cells and seven times more PDGFRβ + /Sca-1 + PPC than HIFko GBM ( Figure 1B) . WT-GBM also contained nearly four times as many EPC as HIFko GBM ( Figure 1B) . Importantly, GFP+ BMDC were comprised of about 8% EPC and 2% PPC, respectively, while up to 90% (about 16% of total cells within the tumor) were positive for the pan-leukocyte marker CD45 ( Figure 1B ). The majority of the CD45+ BMDC were reminiscent of CD11b + monocytes/myeloid cells and F4/80 + macrophages, with ~5% Tie2 + expressing monocytes or VEGFR1+ hemangiocytes ( Figure 1C ). All CD45+ subpopulations were reduced two-to-four fold in HIFko GBM. These results indicate that HIF1 activation results in recruitment of heterogeneous populations of BMDC. Given that all of these cell types are diminished in HIFko GBM, our data suggest that a reduction in the number of BMDC may be the limiting factor in promoting angiogenesis.
HIF1 induces SDF1α in tumor cells
This result raises the question about the signaling events that recruit BMDC in a HIF-dependent manner. Both VEGF, which is implicated in the recuitment of vascular progenitor cells , and stromal-derived factor 1α (SDF1α/CXCL12), which signals through CXCR4 and may retain CXCR4+ BMDC in tumors (Grunewald et al., 2006; Hattori et al., 2003) , are HIF1 target genes (Ceradini et al., 2004; Shweiki et al., 1992) . Indeed, WT-GBM produced about four-fold higher levels of VEGF and SDF1α than HIFko GBM ( Figure 1D ).
While WT-GBM contained clusters of SDF1α+ cells, GBM deficient in HIF1α, contained only a few single SDF1α+ cells in ( Figure 1E ). Importantly, we found that WT-GBM cells, but not HIFko GBM cells, upregulated SDF1α mRNA under hypoxic conditions ( Figure 1F ), suggesting that GBMs, through HIF1 and its target SDF1α, recruit CXCR-4+ BMDC to the tumor site to facilitate new blood vessel growth.
HIF1 recruits MMP-9-positive monocytic cells from the bone marrow
If HIF1-induced BMDC influx regulates neovascularization, then which of the BMDC are functionally significant in this process and how do they achieve angiogenic initiation in GBM? Clearly, EPC and PPC could support new vessel formation in these rapidly expanding GBMs by providing an additional source of endothelial cells and pericytes Rajantie et al., 2004; Song et al., 2005) . However, it is less obvious what roles the heterogeneous CD45+ myeloid cell populations play. Therefore, we used a candidate approach to identify proangiogenic molecules produced or regulated by vascular-modulating CD45+ BMDC. Recent studies have shown that these cells express matrix metalloproteinase (MMP)-9 (Jodele et al., 2005; Page-McCaw et al., 2007; Yang et al., 2004; Nozawa et al., 2006) . We had discovered that MMP-9, conveyed by inflammatory cells, enables an angiogenic switch by making sequestered VEGF bioavailable for its receptor VEGFR2 in pancreatic islet tumors (Bergers et al., 2000; Nozawa et al., 2006) . In human high-grade astrocytomas, MMP-9 expressed in inflammatory cells and the invading tumor cell compartment correlates with poor progression (Hormigo et al., 2006; Kunishio et al., 2003) .
We observed that the expression of MMP-9 in GBM was substantially reduced in the absence of HIF1 (Figure 2A ). Similar to human GBMs, WT-GBM expressed MMP-9 in monocytic inflammatory cells including F4/80+ macrophages and Tie2+, CD11b+ and VEGFR1+ myeloid populations ( Figure 2B ). We also detected MMP-9 in a small subset of tumor cells within the tumor mass and in single tumor cells infiltrating the brain parenchyma, as visualized by double positivity for SV40Tag and MMP-9, which were substantially reduced in the HIFko GBMs ( Figure 2C ). Substrate-gel zymography indicated that most of MMP-9 in the tumors was in an active form in the tumors and that this was reduced in HIFko GBM ( Figure 2D ).
Given that HIFko GBM do not undergo vascular remodeling, we hypothesized that the non-angiogenic behavior of HIFko GBM is mainly caused by the substantial reduction of MMP-9-expressing BMDC in the tumors. The reduced levels of MMP-9 would then keep VEGF in a predominantly sequestered state. Indeed, when we expressed active MMP-9 ectopically in HIFko-GBM cells to increase intratumoral MMP-9 levels ( Figure 2E ), tumors became hemorrhagic ( Figure 2F ) and exhibited to a certain extent a tortuous, irregularly shaped and hyperdilated vasculature indicative of vascular remodeling ( Figure 2G ) and keeping with the observation that an early indication of VEGF activity is vascular hyperdilation (Dvorak, 2000; Sundberg et al., 2001) . Since the VEGF levels in HIFko GBM are about 3.5 fold less than in WT-GBM ( Figure 1D ), the magnitude of these responses would be expected to be limited due the rather low VEGF levels. Thus, although VEGF is liberated from the matrix in the presence of MMP-9, the total VEGF levels are not sufficient to produce the vigorous angiogenesis seen in WT-GBM. Indeed, we confirmed that the soluble VEGF fraction was substantially higher in MMP-9+ HIFko GBM, compared to mock transfectants ( Figure 2H ). Our data suggest that HIF1 regulates two steps of VEGF activity;
i.e., it both induces VEGF levels and regulates its mobilization from the ECM by recruiting monocytes that transport MMP-9 to the tumor site.
MMP-9 deficiency impedes vascular remodeling and neovascularization in GBM
If indeed MMP-9 is a critical downstream factor of HIF1α regulating angiogenesis, then MMP-9 deficiency should give rise to tumors that, like HIFko GBMs, are non-angiogenic. We generated MMP-9 deficient GBMs using the same protocol that we used to produce WT-GBM and HIFko GBMs (Blouw et al., 2003) . Both MMP-9ko GBM and WT-GBM cells gave rise to similar numbers of soft agar colonies (Supplemental Figure 1 ). We then injected MMP-9ko GBMs into MMP-9ko mice, which would then display a system completely depleted of MMP-9 activity. Although MMP-9ko tumors exhibited typical features of highgrade astrocytomas/GBMs and did not differ from WT-GBM in their proliferation rate, these mice exhibited modestly longer survival times than wild type mice bearing WT-GBM (Supplemental Figure 1 ).
We found that the majority of tumor vessels from MMP-9ko tumors were slim and elongated and regularly shaped, as visualized by fluorescent angiography, similar to blood vessels in normal brain tissue, and in contrast to the distorted and angiogenic tumor vasculature from WT-GBM ( Figure 3A ).
Congruent with the morphologic changes of an angiogenic tumor vasculature, we observed VEGF-VEGFR2-complex formation, which marks the activated, angiogenic state (Bergers et al., 2000; Brekken et al., 2000) on endothelial cells ( Figure 3C ) and RGS-5 expression ( Figure 3D ), a marker of activated pericytes (Berger et al., 2005; Bondjers et al., 2003) in WT-GBMs, but not in MMP-9ko tumors ( Figures 3C and 3D ). These results indicate that tumor vessels in the absence of MMP-9 did not undergo vascular remodeling.
Notably, the inability of VEGF to bind to its receptor in MMP9ko tumors was not caused by a severe reduction in VEGF or its receptor VEGFR2 (Figures 3B and 3E, ) because VEGF levels were comparable to those of WT-GBM (Supplemental Figure 2 ). However, most of the VEGF-164, the predominant VEGF isoform in GBM tumors, was bound to the extracellular matrix and cell surface of MMP-9ko tumor cells, and unlike the wildtype GBM was not present in the supernatant ( Figure 3F and G). These data confirm our observation in HIFko MMP-9-overexpressing (HIFko MMP-9+) tumors that MMP-9 is an important initiator of angiogenesis in GBM by releasing sequestered VEGF and making it bioavailable to its receptor VEGFR2.
Bone marrow-derived MMP-9+ cells are sufficient to initiate the angiogenic switch in GBM
To determine whether MMP-9 in tumor cells or host cells is critical for the angiogenic phenotype, we implanted WT-GBM cells into MMP-9ko hosts ( Figure   4A ), and MMP-9ko GBMs into wildtype hosts ( Figure 4B ). In both instances, tumor vessels underwent vascular remodeling exhibiting features of irregularly shaped and tortuous structures and showed VEGF/VEGFR2 binding, albeit to a lesser extent than WT-GBM in WT hosts, indicating that as long as a critical threshold of MMP-9 exists in the tumors, angiogenesis will be initiated. In both instances MMP-9+ cell numbers were reduced to about 50% of that in the wildtype situation ( Figure 4E ). Interestingly, when we injected MMP-9ko GBMs into wildtype mice in which their bone marrow was reconstituted with MMP-9ko bone marrow, MMP-9+ cells in the tumors dropped significantly by 3-4-fold, compared to WT-GBM, and blood vessels were more elongated and slim and did not exhibit VEGF:VEGFR2 activation, mimicking the phenotype of MMP-9ko tumor blood vessels in a MMP-9ko host ( Figure 4C , E). Similarly, when we reconstituted the bone marrow of MMP-9ko mice, harboring MMP-9ko tumors, with wildtype bone marrow, the number of MMP-9+ cells increased, blood vessels became enlarged and distorted exhibiting typical features of vascular remodeling concomitant with VEGF binding to its receptor ( Figure 4D , E).
These data support the notion that a specific MMP-9 threshold is required for the angiogenic switch and that indeed BMDCs expressing MMP-9 have a significant effect on GBM angiogenesis. There are several possibilities as to how MMP-9+ BMDCs make GBMs highly angiogenic: MMP-9 in the bone marrow could be critical in enabling mobilization of endothelial progenitor cells. This mechanism, albeit not proven, has also been suggested for pericyte progenitor cells (Jodele et al., 2005) . Alternatively, MMP-9 carried in by infiltrating BMDC cells, may be more important at the tumor site, where it can mobilize VEGF and thereby initiate angiogenesis.
MMP-9 enables recruitment of EPC and PPC to the GBM vasculature
To elucidate how MMP-9+ BMDC promote GBM angiogenesis, we analyzed whether lack of MMP-9 in bone marrow cells impacts recruitment of vascular progenitor cells and CD45+ myeloid vascular support cells. Transplant experiments with actin-GFP bone marrow cells revealed a four-fold reduction of VEGFR2+ GFP+ EPC incorporated into tumor vessels when compared to WT-GBM ( Figure 5A ). Using two different pericyte markers (desmin and α-smooth muscle actin [α−SMA]) to detect pericytes ( Figure 5B ), we also observed about a 50% reduction in pericyte coverage in the absence of MMP-9. Upon reconstitution of the bone marrow of MMP-9ko GBM-bearing MMP-9ko mice with wildtype bone marrow, pericyte coverage increased, approximating the wildtype situation ( Figure 5B ). In contrast, when we reconstituted bone marrow of wildtype tumor-bearing mice with MMP-9ko bone marrow, we lowered pericyte coverage, indicating that a subpopulation of pericytes is recruited from the bone marrow in an MMP-9 dependent manner ( Figure 5B ).
Recruitment of CD45+ cells is independent of MMP-9 but dependent of
SDF1α
We then asked whether MMP-9 is also required for recruitment of the CD45+ population of BMDC in GBM. We observed similar numbers of CD45+ cells in MMP-9ko GBM and WT-GBM tumors ( Figure 5C ). By contrast, we observed a ~three-fold reduction in the number of CD45+ and F4/80+ cells in HIFko GBMs when compared to wildtype tumors ( Figure 5C ). While WT-GBM and MMP-9ko GBM expressed comparable levels of SDF1α, GBM that were deficient in HIF1α expressed severely reduced levels of SDF1α, reflective of the differing CD45+ cell influx in the respective tumors ( Figure 5C ). These data suggest that GBMs recruit CXCR4+ BMDC to the tumor site through HIF1 and its target SDF1α to facilitate new blood vessel growth.
To show the functional significance of SDF1α in neovascularization , we treated WT-GBM bearing mice with the CXCR-4 inhibitor AMD3100 (Petit et al., 2007) . AMD3100 substantially reduced the recruitment of CXCR4+/CD45+ BMDC ( Figure 5D ) and tumor vessels appeared slimmer and "normalized" as observed when angiogenesis is inhibited ( Figure 5E ).
BMD-CD45+ cells are sufficient to initiate neovascularization in GBM
Since AMD3100 also blocks CXCR4+ EPC, we sought to investigate whether the CXCR4+ monocytic population is functionally significant and sufficient in promoting the angiogenic switch. In contrast to the EPC and PPC populations, that both were reduced in MMP-9ko GBM, we found that MMP-9ko GBM and WT-GBM contained similar numbers of CD45+ BMDC ( Figure 5C ), indicating that recruitment of these monocytic cells is independent of MMP-9 in the bone marrow. This suggested that MMP-9ko tumors were non-angiogenic, despite the unaltered levels of monocytic cells, because CD45+ cells lacked MMP-9 necessary to initiate neovascularization, whereas HIFko tumors were nonangiogenic because they had reduced numbers of CD45+ cells and thus, insufficient MMP-9 to initiate neovascularization. To assess the functional significance of MMP-9 in initiating tumor angiogenesis in the whole BMD-CD45+ population, we isolated MMP-9 proficient GFP+ CD45+ cells from bone marrow of wildtype mice and injected them intravenously into MMP-9ko mice bearing MMP-9ko tumors ( Figure 5F ). We used MMP-9 deficient GFP+ CD45+ cells as controls. We confirmed by zymogram analysis that injections of MMP-9 proficient CD45+ cells led to MMP-9 activity in the tumor, whereas injection of MMP-9ko deficient CD45+ cells did not ( Figure 5G ), and that tumors recruited GFP+ CD45+ MMP-9 proficient or deficient cells at similar levels ( Figure 5H ).
The tumors that attracted CD45+ MMP-9+ BMDC changed their vascular phenotype by producing hyperdilated and more irregularly shaped vessels, whereas tumors that attracted CD45+ MMP-9ko cells did not alter the vascular anatomy and the blood vessels remained slim ( Figures 5I and 5J ). Notably, we often detected MMP-9+ cells encircling enlarged tumor vessels ( Figure 5J ), suggesting that MMP-9 may preferentially facilitate local "activation" of sequestered VEGF. We further noticed that VEGFR2 activation occurred in tumors undergoing vascular remodeling, but not in tumors that received CD45+MMP-9ko cells ( Figure 5K ). Taken together with the results in Figures 3 and 4, these data reveal that MMP-9 expressed and secreted by a heterogeneous group of CD45+ cells from the bone marrow is sufficient to initiate angiogenesis by making sequestered VEGF bioavailable to its receptor VEGFR2.
VEGF is a direct and negative regulator of perivascular tumor invasion
In view of our previous observation that genetic ablation of the key angiogenic factors HIF1α or VEGF (Blouw et al., 2003) , which blocks the ability of GBM to initiate VEGF-dependent neovascularization, results in a more invasive phenotype, we re-evaluated the paradigm of angiogenesis as being key to tumor progression. Important to note is that the induced invasive mode in the absence of these angiogenic factors was distinct from the invasive mode in WT-GBM because tumor cells predominantely move on the outside along blood vessels in the brain parenchyma (Blouw et al., 2003 and data shown; Figure 6A white arrows). In contrast, WT-GBMs have more an infiltrative behavior in which tumor cells percolate as single cells through the brain parenchyma ( Figure 6A yellow arrows). Interestingly, we found that MMP-9 was expressed in a subset of these infiltrating cells, while MMP-9 was not detected in HIFko GBMs that migrated along blood vessels ( Figure 2C ). These data support the hypothesis that MMP-9 facilitates infiltration of tumor cells directly, but is not implicated in the perivascular invasive mode. In addition, we predicted that MMP-9ko GBMs should display a more perivascular invasive phenotype given that these tumors do not undergo vascular remodeling. We observed that GBM grew more diffusively into the brain parenchyma in the complete absence of MMP-9 and subsequent lack of neovascularization ( Figure 6A ). While WT-GBMs in a wildtype host and WT-GBMs in an MMP-9 deficient host both preferentially infiltrated into the brain parenchyma, loss of MMP-9 in the tumor cell compartment, only, was sufficient to tip the balance to a more perivascular invasive mode, which was even more exaggerated in the complete absence of MMP-9, comparable to the phenotype observed in HIF1-deficient tumors ( Figure 6B) ; notably, whether either HIF1α or MMP9 was completely ablated, angiogenesis was disabled and then perivascular invasion became most prominent.
These results point to a specific adaptation mechanism for GBM when deprived of key angiogenic factors that drive VEGF-dependent neovascularization and suggest that the mechanisms of tumor cell infiltration and perivascular tumor cell invasion are very distinct. Since perivascular tumor invasion is negatively correlated with angiogenesis, we then tested the hypothesis that VEGF is the negative regulatory factor. Indeed, by ectopically expressing VEGF-164, the major VEGF isoform expressed in GBM, we were able to convert HIFko GBMs, which are highly invasive and produce low levels of VEGF, into non-invasive tumors with smooth borders ( Figure 6C ).
How does VEGF-induced angiogenesis block perivascular invasion?
Based on several reports that tumor cells can express VEGF receptors (Lesslie, 2006; Rao, 2006) , we asked whether VEGF has a direct effect on the invasive behavior of GBM. We assessed the WT-GBM and HIFko GBM tumor cell lines for expression of VEGF receptors and co-receptors. We observed that the tumor cell lines expressed, to varying extents VEGFR1 and 2, and neuropilin-1 (NP-1) and neuropilin-2 (NP-2) ( Figure 6D ). Encouraged by these results, we tested the ability of VEGF to affect invasive behavior of GBM cells directly in vitro in a Boyden chamber assay. Both WT-GBM and HIFko GBM cells were highly invasive in response to HGF, a stimulator of GBM invasion (Abounader and Laterra, 2005; Eckerich et al., 2007) , but surprisingly, VEGF reduced their invasive behavior significantly ( Figure 6F ). Similarly, HIFko GBM cells overexpressing VEGF were less invasive than their wildtype counterparts ( Figure   6E ). VEGF alone did not stimulate or inhibit invasiveness of GBM cells. In summary, these results reveal that VEGF acts as a direct negative regulator of perivascular GBM tumor cell invasion.
DISCUSSION
HIF1 is a key regulator for BMDC recruitment in tumors
In this study, we have demonstrated that HIF1, in part, by inducing SDF1α, is a major recruitment regulator of bone marrow-derived EPC, PPC and monocytic vascular modulatory cells to endorse vascular remodeling in glioblastomas ( Figure 7) . HIF1 not only induces VEGF transcription in GBM, but also increases VEGF activity by recruiting CD45+ BMDC that carry and secrete the metalloproteinase MMP-9 to the tumor site, which in turn makes sequestered VEGF bioavailable for its receptor VEGFR2 (Figure 7 ). We found that MMP-9 was expressed in all the CD45+ monocytic cell types that have been implicated in angiogenesis, including TEMs, VEGFR1+ hemangiocytes, CD11b+ immature myeloid cells and TAMs. These data suggest that MMP-9 is a critical key molecule for the different CD45+ vascular modulating cells to promote angiogenesis. Our result that MMP-9 expressed by CD45+ cells is necessary and sufficient to drive neovascularization supports this conclusion. We noticed that most VEGFR1+ hemangiocytes and TEMs express MMP-9 which may explain why inhibition of these cells impairs neovascularization, although these cell types constitute less than 10% of the CD45+ population (De Palma et al., 2005; Jin et al., 2006; Rafii et al., 2002) . Importantly, our study indicates that tumors need to have a threshold of MMP-9 levels to initiate the angiogenic switch.
We further revealed that not only the recruitment of EPC, but also that of PPC into tumors depended on HIF1 activity and was regulated by MMP-9. PPCs are critical for supplying tumor vessels with sufficient pericytes and for supporting vessel stability and endothelial cell survival in tumors (Song et al., 2005) .
In contrast to several other studies (Jin et al., 2006; Jodele et al., 2005) , we did not observe that MMP-9 impacted the recruitment of CD45+ BMDCs, although HIF1 activity did. One explanation for the different recruitment mechanisms may lie in distinct signaling circuits that drive recruitment of the respective BMDCs. In our study, HIF1-induced VEGF and SDF1α in tumor cells dictated the influx of BMDCs. While VEGF is an important factor for the activation of MMP-9 in the bone marrow and subsequent mobilization of vascular progenitor cells , SDF1α may be crucial for retaining CD45+ populations within the tumor (Grunewald et al., 2006) (Petit et al., 2007) . This may explain why tumors growing in a completely MMP-9 deficient environment, which has comparably high SDF1α levels, have reduced numbers of EPCs and PPCs that are recruited in response to VEGF activity, but unaltered levels of CD45+ cells. HIFko tumors exhibited reduced levels of both SDF1α and VEGF and recruited fewer vascular progenitors and CD45+ modulatory cells. We conclude that, while HIF1 induces vascular progenitors and monocytic vascular modulatory cells, it is the monocytic population that is sufficient to drive neovascularization.
VEGF regulates invasiveness of tumor cells
Increased bioavailability of VEGF due to influx of MMP-9 expressing CD45+ cells not only induced angiogenesis, but also regulated tumor cell invasiveness. VEGF prevented tumor cell migration along blood vessels, but appeared to promote tumor cell infiltration into the brain parenchyma. This action of VEGF as a brake on perivascular GBM tumor cell migration is surprising and novel. We observed enhanced invasiveness in the GBM model when VEGF-dependent neovascularization was blocked by genetically deleting the angiogenic regulators VEGF, HIF1α or MMP-9 [ (Blouw et al., 2003) and current data]. Tumor cells dispersed deep into the brain parenchyma by using blood vessels as a freeway system for perivascular tumor invasion. This invasive mode is distinct from single cells infiltrating into the brain parenchyma and suggests differing mechanisms, also supported by the fact that perivascular tumor cell invasion is independent of MMP-9 and MMP-2 (Du et al., in press) . In contrast, infiltrating tumor cells at the invading edge of WT-GBM expressed MMP-9, suggestive of MMP-9 as a direct regulator in tumor cell infiltration. Further support for this hypothesis stems from vitro studies showing that decreasing MMP-9 in GBM cells reduced their invasive capacity (Hu et al., 2007; Lakka et al., 2004) ) How is perivascular invasion regulated by VEGF? Our observation that both MMP-9ko and HIFko GBM are well vascularized with a rather normal and more functional vasculature than the distorted and less dense tumor vasculature of WT-GBMs, suggests that is unlikely that tumor cells move out due to insufficient oxygen and nutrient intake (Blouw et al. 2003) . Alternatively, VEGF could directly signal through tumor cells and thereby affect their migration behavior. Congruently with the observation that a variety of tumors express VEGFR1 or 2 and neuropilins, their co-receptors (Lesslie et al. 2006; Rao, 2003) , we found that GBM cells express VEGFR 1 and 2 and neuropilin 1 and 2, and that addition of VEGF to tumor cells, or the generation of tumor cells that ectopically express high levels of VEGF-164, reduced the migration capacity of tumor cells. Whether VEGFR1 and 2 or neuropilins play a prominent role in regulating tumor cell migration remains to be determined.
Clinical implications
The observation that hypoxia is a driving force in BMDC-dependent neovascularization of tumors has also clinical implications. Hypoxia occurs not only in certain tumor types during progression, but it also in tumors that undergo antiangiogenic therapy due to vessel regression. Therefore, combinatorial treatment modalities blocking both proangiogenic receptor tyrosine kinase signaling circuits and the recruitment of vascular progenitor and modulatory BMDCs may reveal synergistic effects and survival benefit. Similarly, GBM patients undergo daily radiation after surgery to kill as many remaining tumor cells as possible. This treatment might be a double-edged sword because radiation also mobilizes bone marrow cells into the blood stream (Heissig et al., 2005b ) that could account for the fast tumor relapse that often occurs in GBM patients. Our results suggest that radiation should occur in combination with CXCR4 inhibitors or other BMDC targeting agents to block BMDC recruitment and subsequent neovascularization and regrowth of tumors.
Our observation that tumor cells increase their perivascular invasiveness in the absence of VEGF activity was also found in a human GBM xenograft model treated with the VEGF inhibitor SU5416 (Rubenstein et al., 2000) .
Moreover, a pro-invasive adaptation has been inferred from MRI imaging in a subset of GBM patients that had developed multifocal recurrence of tumors during the course of anti-VEGF (bevacuzimab) therapy (Drs. M. Prados and N.
Butowski, UCSF personal communication). These data implicate that GBMs impaired in angiogenesis, for example when targeted with anti-VEGF agents, can evade from their inability to induce angiogenesis by becoming more invasive. We speculate that this adaptation mechanism is unlikely to be restricted to brain tumors but might become apparent in other tumor types when confronted with anti-VEGF agents. It will therefore be instrumental to identify pathways that simultaneously block perivascular invasion and angiogenesis to improve current anti-angiogenic therapeutic implications in tumors.
Experimental procedures
Generation of WT-GBM, HIFko GBM, HIFko MMP-9+, and MMP9ko GBM transformed mouse astrocytes
WT-GBM and HIFko GBM transformed mouse astrocytes have been described previously (Blouw et al., 2003) . MMP-9ko GBM cells were generated using the same approach. Briefly, primary astrocytes were isolated from 1-to 2-day-old MMP-9 ko/ko FvBN Ragko mice by removal of the meninges, followed by digestion of the hippocampus with papain. Single cell suspensions of the digested tissue were then washed and cultured in astrocyte medium (MEM supplemented with 10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, 0.6% glucose). Cells were grown at 37°C in a humidified incubator containing 5% CO 2 and the purity of primary astrocytes confirmed with an anti-GFAP antibody. Astrocytes were then immortalized by transfection with a SV-40 Large T antigen construct followed by stable selection with 300 µg/ml G418 (Invitrogen, Carlsbad, CA). Resistant colonies were pooled and transformed by retroviral transduction of the H-Ras oncogene. Stable transformed colonies were selected with 1 µg/ml Puromycin (Sigma, St. Louis, MO), and thereafter cells were routinely cultured in astrocyte medium containing 5% FBS. HIFko MMP-9+ cells overexpressing MMP-9 were generated by retroviral transduction of HIFko GBM cells with an autoactivating form of MMP-9 (kind gift from Dr. Elaine Raines) as previously described (Gough et al., 2006) . Single cell clones were isolated by limiting dilution and screened for MMP-9 overexpression by gelatin zymography.
As controls for MMP-9 overexpressing cells, HIFko Mock control cells were generated in the same fashion using an empty retroviral construct, and their MMP-9 expression level subsequently confirmed to be identical to parental HIFko GBM cells.
Bone Marrow Transplantation
Six-to eight-week old β-actin-EGFP Rag1ko mice were sacrificed and their bone marrow harvested by flushing the femurs and tibias with 2% FBS in PBS. 2 x 10 6 cells were intravenously injected through the tail vein of lethally irradiated (10 Gy) recipient mice. Intracranial tumor cell implantation was performed four weeks later.
Intracranial implantation of astrocytes
80 FvBN Rag1ko mice, 6 to 8 weeks of age, were each intracranially implanted with 2.5 µl of 0.7 x 10 6 WT-GBM or HIFko GBM transformed astrocytes.
Similarly, 15 MMP-9ko mice (6 to 8 weeks of age) were injected with MMP9ko GBM cells, while 10 FvBN Ragko mice were injected with MMP9ko GBM cells and 9 MMP9ko mice were injected with WT-GBM cells. 8 FvBN Rag1ko mice were injected with HIFko MMP-9+ cells, while 5 mice were injectd with HIFko MMP-9 Mock cells.. Transformed astrocytes were injected using a Hamilton syringe 3 µm to the right of the midline behind the breegma and exactly 2 µm deep into the brain parenchyma. All mice were sacrificed 14-21 days after tumor cell implantation when they exhibited weight loss or lateral recumbency, at which point mouse brains and tumors were isolated and prepared for flow cytometric analyses, immunohistochemical staining, or protein and RNA isolation as described below. All implantation experiments were repeated up to 3 times for a total of 5 to 10 mice per group.
AMD3100 treatment
10 FvBN Rag1ko mice intracranially injected with WT-GBM transformed astrocytes were evenly randomized into two cohorts for AMD3100 treatment or vehicle/control treatment. Beginning 3 days prior to tumor cell implantation, AMD3100 (Sigma) was subcutaneously administered at 1.25 mg/kg twice daily in the right and left flank, with at least 6 hours between doses. 1x PBS was administered in the same manner for control animals. Treatment continued daily for 2 weeks after tumor injection, with the exception of single doses on weekends, at which point the animals were sacrificed and brains harvested.
AMD3100 treatment experiments were performed 4 times, for a total of 20 treated animals and 20 control animals.
Isolation of GFP+ CD45+ Bone Marrow Cells
CD45+ cells were isolated from the bone marrow of MMP-9 +/+ β−actin-EGFP Ragko mice or MMP9 ko/ko β−actin-EGFP Ragko mice using a biotinylated rat antibody against murine CD45 and the EasySep Biotin Selection Kit (StemCell Technologies). 2 x 10 6 of the isolated GFP+ CD45+ bone marrow cells were then intravenously injected through the tail vein of MMP-9 ko/ko mice that were intracranially implanted with 0.7 x 10 6 MMP9ko GBM cells earlier the same day. CD45+ cells were isolated and intravenously injected every 3-4 days thereafter for a total of 4 injections over 2 weeks, at which time mice were sacrificed for analysis. CD45+ cell supplementation experiments were repeated four times with a total of 4 to 5 mice per group.
Flow Cytometry
Brains from GFP-bone marrow transplanted mice were removed and the tumors trimmed, minced, and digested with 20 µl enzyme mixture containing 1 µg/ml 
Tissue preparation
To prepare tissues for immunohistochemical staining, mice were anesthetized and cardiac-perfused with phosphate buffered saline (PBS) and 4% paraformaldehyde (PFA). Brains were removed and fixed in zinc-formalin overnight, then immersed in 70% ethanol and embedded into paraffin.
Alternatively, brains were fixed in 4% PFA for 12 hours, immersed in 30% sucrose/PBS overnight, then embedded in OCT freezing medium and stored at -80°C.
Immunohistochemistry
Frozen (14 µm thickness) and paraffin (6 µm thickness) sections were used for immunohistochemical analysis. Fixed frozen sections were air-dried and postfixed with 4% PFA, and paraffin sections were deparaffinized and subjected to graded rehydration. Astrocytoma cells were identified with a rabbit anti-SV40 Tag antibody (1:500; gift from Dr. Douglas Hanahan, UCSF). To visualize the vasculature, mice were intravenously injected with FITC or Rhodamineconjugated lectin prior to PBS/PFA heart perfusion and fixation. Vessel imaging on frozen sections was subsequently enhanced by staining sections with a 1:100 dilution of a rat anti-mouse CD31 antibody (BD Biosciences). BMDC populations were analyzed on frozen sections by staining with 1:500 dilutions of rat antimouse CD45 and CD11b (BD Biosciences), 1:100 Tie-2 (eBioscience), 1:500 F4/80 (Serotec, Raleigh, NC), and 1:150 VEGFR1 clone MF1 (Imclone Systems) antibodies. MMP-9 was detected with a 1:500 dilution of a rabbit anti-MMP-9 antibody (Behrendtsen and Werb, 1997) . Staining of SDF1α was also performed on frozen sections using a rabbit anti-SDF1α antibody (1:100, Cell Sciences, Canton, MA). VEGFR2 staining was carried out on paraffin-embedded sections with a goat anti-mouse VEGFR2 antibody (1:50, R&D Systems). VEGF-VEGFR2 complex was visualized in frozen sections with a mouse monoclonal antibody For α-SMA staining, 4 to 9 tumor sections per group were evaluated.
Substrate Zymography
Tumors were trimmed out of the brain, weighed, then homogenized ( 25% glycerol, 0.1% Bromophenol Blue, pH 6.8). After electrophoresis, gels were washed for 40 minutes in 2.5% Triton X-100, rinsed in water, and incubated for 16h at 37°C in gelatinase buffer (50 mM Tris-HCl pH 7.5, 5 mM CaCl 2 , 1 µM
ZnCl 2 ). Gels were then stained in Bio-Rad Coomassie Brilliant Blue R-250
Staining Solution (Bio-Rad, Hercules, CA) and destained in destaining solution (30% ethanol, 10% acetic acid). Negative staining denotes the locations of active proteinase bands. 20 mM EDTA was added to the gelatinase buffer overnight to confirm that the proteases were metalloproteinases.
RNA isolation, RT-PCR, and real-time PCR analysis
RNA isolation was performed on cell cultures or whole tissue. Whole tissues were flash frozen in liquid nitrogen and stored at -80°C until required. After thawing tissues on ice, 1 ml of TRIzol Reagent (Invitrogen) was added and the tissue was homogenized immediately using a rotor-stator homogenizer (Fisher Scientific, Pittsburg, PA). For cell cultures, TRIzol Reagent was added directly to adherent cells on the dish after rinsing with PBS. Total RNA was harvested as per the manufacturer's instructions. First-strand cDNA was generated using the SuperScript II First strand Synthesis System (Invitrogen).
The following primer sequences were used: 
Nonradioactive in situ hybridization
Nonradioactive in situ hybridization of RGS-5 was performed as published previously (Berger et al., 2005) 
Extraction of VEGF and immunoblotting
Supernatants of 70% confluent WT GBM and HIFko GBM cells were collected for 20 hours in serum-free medium and Insulin-Transferrin-Selenium and concentrated 50-fold in a microconcentrator (Millipore). Cell extracts were prepared by gently scraping off cells in 1x calcium and magnesium-free phosphate-buffered saline followed by extraction in RIPA buffer containing 1 x protease inhibitors (Roche) as described (Du et al., Neuro-Oncology in press, 2007) . Extracellular matrix proteins were extracted after complete removal of cells from cell culture dishes in RIPA buffer as described (Park et al.,1993) .
Protein samples (15 µg for cell supernatants, 150 µg for ECM and cell extracts, Concentrations for SDF-1α and VEGF were determined using the Quantikine mouse SDF-1α kit and mouse VEGF kit (R&D Systems), respectively.
Invasion assay
50% confluent HIFko or WT-GBM or HIFko-VEGF astrocytoma cells were switched to serum-free DMEM medium containing no VEGF or VEGF (50ng/ml) for 18 h, trypsinized and seeded at 1 x 10 5 cells/well in 24-well matrigel plates (Fluroblock; BD Falcon) in medium containing 40ng/ml HGF with either no VEGF or 100 ng/ml VEGF in the lower chamber. Invasion was assayed after 20 h using Calcein AM as substrate on a cytoflour (excitation 485/20; emission 530/35; 50% gain).
Statistical analysis
All experiments were repeated 2 to 4 times. With the help of biostatistician tumors: association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618. A. Immunohistochemical analyses of WT-GBM tumors revealed that about 16% of all cells within a tumor are recruited GFP-labeled BMDCs. In the absence of HIF1 (HIFko GBM), BMDC recruitment is reduced by ~ 4-fold. Ragko mice were inoculated with WT-GBM and HIFko GBM cells after bone marrow transplantation with actin-EGFP+ bone marrow. GFP+ cells were counted in 4-5 randomly selected fields per tumor of 7 WT-GBM or HIFko GBMs 14 days after intracranial tumor cell injection. Angiogenic vasculature in WT-GBMs, as visualized by CD31 staining (red), is characterized by tortuous, hyperdilated and distorted vessels, whereas vessels in non-angiogenic HIFko GBMs which have not undergone vascular remodeling, appear slim and more regular. BMDCs were predominately located around or adjacent to tumor blood vessels. Scale bar, 50 µm. B. Fluorescence activated cell sorting (FACS) analysis of mouse GBM tumors demonstrates that HIF1 recruited three distinct GFP+ BMDC populations to the tumor site: CD45+ monocytes, endothelial progenitors (EPCs: VE-Cadherin+/VEGFR2+) and pericyte progenitors (PPCs: Sca1 + /PDGFRβ + ). While all three populations were reduced in HIFko GBMs (n=4-5/group), the majority of GFP+ BMDCs (up to ~90%) were CD45+ monocytic cells. Results are expressed as the percent of cells within a tumor that are positive for both GFP and the listed markers. Error bars indicate SEM. C. Subsets of the GFP+ BMDC population of CD45+ monocytic cells were VEGFR1+, Tie2+, CD11b+ myeloid cells and F4/80+ macrophages (all labeled in red, white arrowheads) as visualized by FACS and immunohistochemical analyses. Scale bar, 50 µm. All CD45+ subpopulations were reduced two-to-four fold in HIFko GBM. (n=3-4/group). Error bars indicate SEM. D. ELISA assay. WT-GBM expressed about four times higher intratumoral VEGF and SDF1α levels than HIFko GBM (n=3-4/group). E. Immunohistochemical analysis of SDF1α. WT-GBM contained clusters of SDF1α+ cells (encircled) within the tumor whereas SDF1α expression in HIFko GBM was limited to a few single cells (white arrows). Scale bar, 50 µm. F. HIF1 induced SDF1α in GBM tumor cells. WT-GBM and HIFko GBM cells were cultured under normoxic (20% pO 2 ) or hypoxic conditions (1% pO 2 ) for 12 hours, harvested, and transcription levels of SDF1α determined by real-time PCR analysis. Error bars indicate SEM.
Figure legends
Figure 2. MMP-9 is expressed in various subpopulations of CD45+ BMDC and in infiltrating tumor cells
A. WT-GBMs contained about 3.5 times more MMP-9+ cells than HIFko GBMs as quantified by immunohistochemical analyses. MMP-9+ cells were counted in 4 randomly selected fields per tumor of 5 WT-GBM or HIFko GBMs 14 days after intracranial tumor cell inoculation. Scale bar, 50 µm. B. MMP-9 was expressed in F4/80+ macrophages, CD11b+ myeloid cells, VEGFR1+ hemangiocytes and in Tie2+ monocytes as demonstrated by RT-PCR analyses of fractionated cell populations from the tumor and by immunohistochemical analyses. Scale bar, 50 µm. C. MMP-9 was expressed in a small subset of tumor cells at the invading edge of WT-GBM but not in the perivascular invasive areas of HIFko GBMs. MMP-9+ cells are labeled in red, SV40 Tag+ tumor cells in blue, and FITC-lectin coupled blood vessels in green. Scale bar, 50 µm. D. Gelatin zymography revealed predominantly active MMP-9 and to a much lesser extent MMP-2 in WT-GBM tumors. In the absence of HIF1, MMP-9 activity was reduced. As controls, recombinant pro-MMP-9 and 2 as well as active MMP-9 and 2 were loaded, and MMP-activity was obliterated in the presence of the MMP-inhibitor EDTA. E. Gelatin zymography. HIFko MMP-9+ cells that ectopically express MMP-9, had a substantially higher MMP-9 activity than mock-infected control. HIFko MMP-9+ cells were generated by retrovirally transducing HIFko GBM cells with an autoactivating form of MMP-9. F. Intracranially implanted HIFko MMP-9+ cells developed very hemorrhagic tumors by gross morphology while HIFko Mock control tumors did not. G. CD31 staining of tumor sections revealed that vessels in HIFko Mock control tumors were slim and elongated vessels whereas vessels in HIFko MMP-9+ tumors were more distorted and hyperdilated reminiscent of an angiogenic tumor vascularure. H. ELISA. Soluble VEGF was measured in GBM in the supernatant whereas sequestered (bound) VEGF was determined both in the ECM and in GBM cells. 16% of VEGF was found to be soluble in HIFko GBM cells while 34% and 48% of VEGF was mobilized in HIFko-MMP9 + GBM in WT-GBM respectively. A. Immunohistochemical analysis of tumor vasculature visualized by FITClectin perfusion and an anti-CD31 antibody (green). In the complete absence of MMP-9, tumor vessels did not undergo vascular remodeling but contained a regular, slim and dense vascular network (yellow arrowheads). B. Immunohistochemical analysis. VEGFR2 expression on tumor endothelial cells was apparent in WT-GBM and MMP-9ko GBM (yellow arrows). C. Immunohistochemical analysis. Activated tumor vessels were detected with the Gv39M antibody that recognizes the VEGF:VEGFR2 complex (brown) in WT-GBM, but not in tumors that were completely deprived of MMP-9. D. In situ RNA hybridization. RGS-5 (blue), a marker for activated pericytes, was expressed in pericytes of WT-GBM, but not in MMP-9ko GBM. E. Bottom panel: VEGF Western blot analysis: The heparin binding form of VEGF (VEGF-164) is the major VEGF isoform in GBM. Its levels are comparable between WT-GBM and MMP-9ko GBM. However, VEGF-164 is predominantly sequestered in the extracellular matrix and bound to cell surfaces of GBM cells when MMP-9 is absent. In the presence of MMP-9, soluble VEGF is also detected in the supernatant of GBM. VEGFko GBM served as negative controls. Top panel: Tubulin Western blot analysis served as a protein loading control for cell extracts. For supernatants and ECM extracts, equal protein amounts were determined by a Micro BCA assay. F. Quantification of soluble VEGF levels as determined by densitometry of VEGF western blots shown in (E). Soluble VEGF was significantly decreased in the absence of MMP-9. G. ELISA. Ratio of soluble VEGF (in supernatant) and sequestered VEGF (ECM and cells) was determined in WT-GBM and MMP-9ko GBM. Soluble, mobilized VEGF was significantly reduced in GBM in the absence of MMP-9 confirming the densitometry analyses in (E).
Figure 4. MMP-9+ BMDCs contribute to the angiogenic switch in GBM
Immunohistochemical analyses (A-D). Tumor vessels were visualized by FITClectin perfusion of mice. The activated tumor vasculature was identified by the presence of VEGF:VEGFR2 complexes on endothelial cells as detected by staining of tumor sections with Gv39M antibody. Cohorts of 6-13 mice were used. A. WT-GBM cells were injected intracranially into MMP-9ko mice. Tumor vessels underwent vascular remodeling as determined by their irregular shape and the presence of a few activated tumor vessels (yellow arrowheads). B. MMP-9ko GBM cells were injected intracranially into wildtype mice. Tumor vessels underwent vascular remodeling as determined by their irregular shape and the presence of a few activated tumor vessels (yellow arrowheads). C. Wildtype mice were lethally irradiated and reconstituted with bone marrow from MMP-9ko mice, then intracranially injected with MMP-9ko GBM cells.
Tumor vessels contained areas of elongated and slim vessels mimicking the phenotype of MMP-9ko tumor vessels and did not exhibit VEGF:VEGFR2 activation on tumor endothelial cells. D. MMP-9ko mice were lethally irradiated and reconstituted with bone marrow from wildtype mice, then intracranially injected with MMP-9ko GBM cells. Tumor vessels underwent vascular remodeling because tumor vessels appeared torturous, hyperdilated and irregularly shaped concomitant with VEGF:VEGFR2 activation on tumor endothelial cells. E. MMP-9+ cells were quantified by immunohistochemistry in tumor sections of the different groups described in A-D. MMP-9 solely expressed by tumor cells or by host cells lowered MMP-9+ cells in GBM by 2-fold (red and yellow bars) compared to the wildtype situation (blue bar). When MMP-9ko GBM cells were implanted into WT host animals that had been transplanted with MMP-9ko bone marrow, MMP-9+ cells further dropped (green bar) whereas when MMP-9ko GBM implanted into MMP-9ko hosts had been reconstituted with WT bone marrow, MMP-9+ cells in GBM increased (purple bar). Therefore, the levels of MMP-9 correlate with the angiogenic phenotype of the tumors described in A-D.
Figure 5. CD45+ MMP-9+ BMDCs are sufficient to initiate angiogenesis in GBM
A. Wildtype mice or MMP-9ko mice were lethally irradiated and reconstituted with bone marrow from actin-GFP wildtype or MMP-9ko mice, respectively, and then injected with WT-GBM or MMP-9ko GBM cells. Endothelial progenitor cell (EPC) recruitment was then quantified and compared between WT-GBMs and GBMs in a completely MMP9-deficient background by eliciting the percentage of VEGFR2+GFP+ cells in VEGFR2+ vessels. MMP-9ko GBM revealed a 4-5-fold reduction of bone marrow-derived EPCs. Immunohistochemical analysis of a WT-GBM tumor section demonstrates the detection of EPCs by their doublepositivity for GFP (green) and VEGFR2 (red), as well as their localization in blood vessels. Cohorts of 5 mice per group were used. B. Tumor sections of the different groups described in Fig.4 A-D were analyzed for the presence of pericytes on tumor vessels as detected by desmin (red) and α-SMA-staining (red) and quantified by assessing the ratios of red-labeled pericytes to green-labeled tumor vessels (anti-CD31 staining). Red and green staining was quantitatively evaluated using ImageJ v1.34 software (NIH). MMP-9ko GBMs growing in a MMP-9 deficient background contained about 50% fewer pericytes on their tumor vessels than WT-GBMs in a wildtype background. When the MMP-9ko host received wildtype bone marrow, MMP-9ko GBM received an increase in pericytes whereas in the opposite scenario when wildtype mice were reconstituted with MMP-9ko bone marrow, pericyte numbers in MMP-9ko GBMs dropped.
antibody. MMP-9ko tumors that recruited MMPkoCD45+ cells did not show VEGF:VEGFR2 complex formations.
Figure 6. VEGF directly inhibits perivascular tumor invasion.
A. MMP-9ko GBMs grew more diffusely into the brain parenchyma than WT-GBMs. Fluorescent detection of tumor cells and vasculature with a SV40-Tag antibody and FITC-lectin, respectively, demonstrates that GBM cells infiltrate as single cells into the brain parenchyma without associating with blood vessels (yellow arrows), or they exhibit perivascular invasion by associating with and invading alongside blood vessels in the brain (white arrows). B. Infiltrative and perivascular invasive modes of GBMs in different tumor cell/host combinations were quantified by immunohistochemical analysis on tumor sections as shown in Fig. 6A . Infiltrative cells were counted as cells in the brain without vessel association whereas perivascular invasiveness of tumor cells was graded from 0-3, where 1 indicates minimal distant spread of tumor cells and 3 indicates substantial and marked distant spread. Five to 8 tumor samples per tumor/host combination were analyzed. C. HIFko GBM were stably transduced with a retrovirus expressing VEGF-164. While intracranially injected HIFko GBMs invaded diffusely and deep into the brain parenchyma by coopting and moving alongside blood vessels (white arrows), HIFko GBMs overexpressing VEGF exhibited a smooth tumor border (dotted line) and did not invade. D. RT-PCR analysis of WT-GBM and HIFko GBM cells and tumors respectively revealed that both tumor cell types express VEGFR1,2 and neuropilin1,2. E. and F. Boyden Chamber invasion assay. GBM cells were incubated in the presence of HGF on a matrigel-coated filter containing 8 µm pores (E). HIFko GBM cells overexpressing VEGF were significantly less migratory than parental HIFko GBM cells, as were WT-GBM cells (which express higher levels of VEGF than HIFko GBMs). The addition of recombinant exogenous VEGF to HIFko cells reduced tumor cell migration by about 50% (F). VEGF alone had no effect when compared to medium that does not contain any growth factors (baseline). Assays were performed four times.
Figure 7. HIF-1 is a critical regulator of BMDC recruitment in tumors.
Hypoxia in tumors increases HIF1, which in part, by inducing VEGF and SDF1α in tumor ce lls , re cruits BMDC including EPC, PPC and CD45+ monocytic vascular modulatory cells to endorse vascular remodeling in glioblastomas. SDF1α serves as retention factor of CXCR4+ vascular progenitor and monocytic BMDC in GBM. HIF1 not only induces VEGF transcription in GBM, but also increases VEGF activity by recruiting CD45+ BMDC that carry and secrete the metalloproteinase MMP-9 to the tumor site, which in turn makes sequestered VEGF bioavailable for its receptor VEGFR2.
Supplemental Figure 1 . In vitro and in vivo characterization of WT-GBM and MMP9ko GBM cells.
A. WT-GBM and MMP-9ko GBM cells formed similar numbers and sizes of colonies in a soft agar colony formation assay. B. Proliferation rate of WT-GBM and MMP-9ko GBM was assessed immunohistochemically by counting Ki67 positive cells on tumor tissue sections. No significant difference was observed. C. WT-GBM cells were intracranially injected into wild type host mice, while MMP-9ko GBM cells were injected into MMP9ko animals. Mice with tumors completely devoid of MMP-9 showed a modest but significant increase in survival time compared to their wild type counterparts.
Supplemental Figure 2: VEGF levels in WT-GBM, HIFko, and MMP-9ko GBM.
Intratumoral VEGF levels were determined by ELISA. While WT-GBM and MMP-9ko GBM exhibited comparable VEGF levels, VEGF was substantially reduced in HIFko GBM.
Supplemental Figure 3. SDF-1α serum and plasma levels of WT-GBM and
HIFko-GBM bearing mice. Serum and plasma of WT-GBM and HIFko-GBM bearing mice was taken and SDF-1α levels assessed by ELISA. No significant changes in SDF-1α levels were observed in the blood between WT-GBM and HIFko GBM mice.
